
|Articles|May 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Advertisement
EAST HANOVER, New JerseyNovartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.
Articles in this issue
almost 20 years ago
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedulealmost 20 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentalmost 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaalmost 20 years ago
New Imaging, ChemoRT Recommendations From NCCNalmost 20 years ago
Panitumumab Improves PFS in Advanced Colon Caalmost 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsalmost 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Canceralmost 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespalmost 20 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisalmost 20 years ago
IND Submitted for CYT-500Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5



































